Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Test

Set Alert for Cardiovascular

Test

Set Alert for Scrip Cancer

Latest From Cancer

Spectrum Reshuffles Focus, Selling Seven Products To Aurobindo

By selling seven approved oncology/hematology products to a US affiliate of Aurobindo, Spectrum gets cash to increase focus on late-stage candidates Rolontis for neutropenia and poziotinib for solid tumors.

Cancer Commercial

J&J’s Erleada Gives Chase To Xtandi For Non-Metastatic Prostate Cancer With Approval In Europe

Astellas/Pfizer’s Xtandi and Johnson & Johnson’s Erleada are both now approved for non-metastatic castration-resistant prostate cancer in Europe, while Xtandi benefits from physician familiarity, Erleada has shown greater metastasis-free survival.

Cancer Approvals

Biotech Showcase 2019: Harnessing IgE Antibodies To Tackle Solid Cancers

Immuno-oncology is currently one of the hottest spaces for biotechs and so to rise above the noise companies need to be truly differentiated. Speaking on the sidelines of Biotech Showcase 2019, Tim Wilson, CEO of Cambridge, UK-based IGEM Therapeutics, tells Scrip how his company is achieving this by developing IgE antibody drugs to fight cancer, with its lead program against ovarian cancer already in Phase I testing.

ImmunoOncology Innovation

Merck’s Keytruda Shows Utility In Subset Of Esophageal Cancer

A Phase III study testing Keytruda monotherapy in second-line esophageal cancer versus physician’s choice of chemotherapy shows a 31% reduction in risk of death for patients expressing PD-L1. [Editor's Note: Article updated to clarify trial outcomes.]

Clinical Trials ImmunoOncology

Loxo Links And Colorectal Cancer Data Put Array In M&A Spotlight

Following Lilly's proposed acquisition of Loxo, other possible takeover targets in the precision medicine field have emerged and Array, armed with more positive data on its colorectal cancer triplet, is near the top of the list.

M & A Cancer

Roche Calls For Harmonized Regulation As Subcutaneous Herceptin Is Denied Trial Waiver In India

Roche’s subcutaneous (SC) Herceptin (trastuzumab) has been declined a trial waiver in India, at least for now, stretching potential launch timelines for the product significantly. The company emphasizes that a harmonized regulatory approach could best serve patient interests for therapies like Herceptin that come with a ‘long history of proven efficacy’.

Policy & Regulation Clinical Trials
See All
UsernamePublicRestriction

Register